Mitochondria-targeted antioxidant SkQ1 inhibits leukotriene synthesis in human neutrophils

Galina F. Sud‘ina1*, Ekaterina A. Golenkina1, Anastasia S. Prikhodko1, Natalia D. Kondratenko2, Tatjana V. Gaponova3 and Boris V. Chernyak1*

1Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia, 2Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia, 3National Research Center for Hematology, Russia Federation Ministry of Public Health, Moscow, Russia

Leukotrienes are among the most potent mediators of inflammation, and inhibition of their biosynthesis, is becoming increasingly important in the treatment of many pathologies. In this work, we demonstrated that preincubation of human neutrophils with the mitochondria targeted antioxidant SkQ1 (100 nM) strongly inhibits leukotriene synthesis induced by three different stimuli: the Ca2+ ionophore A23187, the chemotactic formyl-peptide fMLP in combination with cytocholasin B, and opsonized zymosan. The SkQ1 analogue lacking the antioxidant quinone moiety (C12TPP) was ineffective, suggesting that mitochondrial production of reactive oxygen species (ROS) is critical for activating of leukotriene synthesis in human neutrophils. The uncoupler of oxidative phosphorylation FCCP also inhibits leukotriene synthesis, indicating that a high membrane potential is a prerequisite for stimulating leukotriene synthesis in neutrophils. Our data show that activation of mitogen-activated protein kinases p38 and ERK1/2, which is important for leukotriene synthesis in neutrophils is a target for SkQ1: 1) the selective p38 inhibitor SB203580 inhibited fMLP-induced leukotriene synthesis, while the ERK1/2 activation inhibitor U0126 suppressed leukotriene synthesis induced by any of the three stimuli; 2) SkQ1 effectively prevents p38 and ERK1/2 activation (accumulation of phosphorylated forms) induced by all three stimuli. This is the first study pointing to the involvement of mitochondrial reactive oxygen species in the activation of leukotriene synthesis in human neutrophils. The use of mitochondria-targeted antioxidants can be considered as a promising strategy for inhibiting leukotriene synthesis and treating various inflammatory pathologies.

KEYWORDS

neutrophil, mitochondria, intracellular calcium, 5-lipoxygenase, leukotriene B4
Introduction

Neutrophils are the first to respond to infections and tissue damage. Neutrophils generate and release leukotrienes, first of all, leukotriene B4 (LTB4), which makes neutrophil’s contribution to the inflammatory state (Peters-Golden and Henderson 2007). Leukotriene B4-mediated recruitment of leukocytes and production of inflammatory cytokines are critical in chronic inflammation and sepsis. Serum LTB4 concentrations are elevated in sepsis and contribute to endothelial disorders. LTB4-mediated swelling and clustering results in severe capillaritis and lethal fungal sepsis; but tissue injury is minimized by blockade of the leukotriene LTB4 (Lee et al., 2018). In our body neutrophils are the most reach source of physiologically active compounds, leukotrienes. 5-LOX is mostly expressed, and neutrophils and monocyte/macrophages. These cells produce LTB4 to stimulate chemotaxis of phagocytes to inflammatory loci. LTB4 is an important mediator of neutrophil inflammation (Kim et al., 2006; Okunishi and Peters-Golden 2011; Tan and Weninger 2017). LTB4 from neutrophils can lead to increased local LTB4 production, neutrophil recruitment and swarming, and act as a cell-to-cell signaling molecule (Nemeth and Mocsai 2016; Subramanian et al., 2017).

LTB4 is formed from arachidonic acid under the action of the enzymes 5-lipoxygenase (5-LOX) and leukotriene A4 hydrolase (Samuelsson and Funk 1989). 5-LOX is the key enzyme in the activation of leukotriene synthesis, and many factors work in concert to stimulate 5-LOX activity. The enzyme 5-LOX binds calcium (Hammarberg and Radmark 1999; Hammarberg et al., 2000) and leukotriene synthesis is potently stimulated by an increase of intracellular calcium [(Ca2+)i]. Calcium also protects 5-LOX from inhibiting action of glutathione peroxidases (GPx) (Bair et al., 2012); phosphorylation by protein kinase A (PKA) leads to the loss of enzyme activity (Luo et al., 2004). Oxidative events play an important role in 5-LOX activation. In particular, the oxidation of Fe2+ to Fe3+ at the 5-LOX active site, which is required for enzymatic activity, is mediated by lipid hydroperoxides (Rouzer and Samuelsson 1986; Rådmark 2002). Oxidative stress (oxygen-glucose deprivation (OGD)/recovery or exogenous hydrogen peroxide) has been shown to induce 5-LOX activation in 5-LOX-transfected PC12 cells (Li et al., 2009). Exogenous hydrogen peroxide or reactive oxygen species (ROS) produced by neutrophils stimulated 5-LOX in the Epstein-Barr virus transformed B-lymphocytic cell line (Werz et al., 2000b). At the same time the excess of hydrogen peroxide has been shown to inhibit 5-LOX activity in alveolar macrophages due to depletion of ATP (Sporn and Peters-Golden 1988). These findings likely explain the paradoxical stimulation of LTB4 synthesis by the antioxidant N-acetylcysteine (NAC) or catalase in alveolar macrophages and in neutrophils (Dent et al., 1997).

Mitochondria are an important source of ROS in various cell types, but only in our previous studies (Vorobjeva et al., 2017; Vorobjeva et al., 2020) mitochondrial ROS (mtROS) were introduced into the regulation of neutrophil functions, including activation NADPH oxidase, degranulation, and the formation of extracellular traps (NETs). In that studies, the mitochondria-targeted antioxidant SkQ1 [10-((6′-plastoquinonyl)decyltriphenylphosphonium bromide) was found to prevent the activation of neutrophils by A23187 and fMLP. SkQ1 selectively accumulates in mitochondria due to the positive charge of the decyltriphenylphosphonium residue and efficiently scavenges mtROS due to the antioxidant activity of plastoquinyl residue (Antonenko et al., 2008). In this study, we found that the mitochondria targeted antioxidant SkQ1 suppresses leukotriene synthesis in human neutrophils activated by A23187, fMLP or opsonized zymosan, suggesting that mitochondrial ROS (mtROS) production is critical for 5-LOX activation.

Materials and methods

SkQ1 (10-((6′-plastoquinonyl)decyltriphenylphosphonium bromide) was synthesized as described earlier (Antonenko et al., 2008). SkQ1 and Dodecyltriphenylphosphonium bromide (C12TPP) were kindly provided by the Institute of Mitoengineering, Lomonosov Moscow State University. Hank’s balanced salt solution with calcium and magnesium but without Phenol Red and sodium hydrogencarbonate (HBSS), Dulbecco’s phosphate-buffered saline (PBS) with magnesium but without calcium, fibrinogen from human plasma, A23187, Dimide (Azodicarboxylic acid bis (dimethylamide)), cytochalasin B and peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) were purchased from Sigma (Steinheim, Germany). MitoQ (Mitoquinone mesylate, S8978) was purchased from Selleck Chemicals (Houston, TX, United States). Zymosan A from Saccharomyces cerevisiae was purchased from Goldbio (St Louis MO, United States). Zymosan was opsonized immediately before the experiment for 30 min in fresh serum from the same donor whose blood was used for neutrophil isolation and washed by repeated centrifugation in Dulbecco’s solution. Acetoxymethyl-ester (AM) conjugated fura-2 was from Thermo Fisher Scientific (Waltham, MA United States).

Neutrophil preparation

Human polymorphonuclear leukocytes (PMNLs) were obtained from freshly collected blood with citrate anticoagulant. Experimental and the subject consent procedures were approved by the Bioethics

Frontiers in Pharmacology frontiersin.org 02

Sud'ina et al. 10.3389/fphar.2022.1023517
Committee of the Lomonosov Moscow State University, Application # 6-h, version 3, Bioethics Commission meeting # 131-d held on 31.05.2021. Leukocyte-rich plasma was prepared from donor blood by sedimentation in the presence of dextran T-500 (Pharmacosmos, Holbæk, Denmark), and granulocytes were obtained as described (Aleksandrov et al., 2006). Cell viability was tested by exclusion of trypan blue. PMNLs (96%–97% purity, 98%–99% viability) were stored at room temperature in Dulbecco’s PBS containing 1 mg/ml/m glucose.

**Determination of 5-LOX product synthesis in intact cells and in cell homogenate**

PMNLs (1 ml × 10^6/6 ml HBSS/HEPES) were kept 10 min at 37°C in CO2 incubator, then reagents were added for 30 min, as indicated, followed by adding of 5-LOX stimul A23187 (1 µM), or cytochalasin B (5 µM) followed by FMLP (0.1 µM), or opsonized zymosan (0.04 mg/ml). The incubation was stopped by adding of an equal volume of methanol (−18°C) with 90 µg PGB2 as internal standard. Major metabolites of 5-LOX, 5S,12R-dihydroxy-6,14-cis-8,10-trans-eicosatetraenoic acid (LTB₄), iso-LTB₄ (5S,12SR-all-trans-diHETE) (t-LTB₄), ω-OH-LTB₄, ω-COOH-LTB₄ and 5S-hydroxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HETE) were identified as previously described (Golenikina et al., 2021).

For the determination of 5-LOX product formation in cell homogenates, freshly isolated PMNLs were resuspended in Buffer A (50 mM K2HPO4, 100 mM NaCl, 2 mM EDTA, 1 mM dithiothreitol, pH 7.1) containing 0.5 mM phenylmethylsulfonyl fluoride and 60 µg/ml soybean trypsin inhibitor, as published (Coffey et al., 1992) and sonicated (3 s × 10 s) on ice. Cell sonicates were centrifuged at 4°C for 10 min at 37°C in CO2 incubator, then reagents were added for 30 min, as indicated, followed by adding of 5-LOX stimul A23187 (1 µM), or cytochalasin B (5 µM) followed by FMLP (0.1 µM), or OZ (0.04 mg/ml, 10 min) were added. PMNLs were lysed in hot 2x Laemmli Sample Buffer. Equal amounts of protein (=20 µg total protein per lane), separated onto 12% SDS polyacrylamide gels and then transferred to PVDF membranes (Amersham, United States). Membranes were probed with antibodies against p-38, phospho-p38, ERK1/2, phospho-ERK1/2 (Cell Signaling, United States, ## 9212S, 9211S, 9102S, and 9101S, respectively). Membranes were treated with goat anti-rabbit HRP-conjugated secondary antibody (Sigma, United States) and developed with ECL extended duration substrate (ThermoFisher, United States) according to the manufacturer’s protocol. ChemiDoc System (Bio-Rad, United States) and appropriate software were used for visualizing and blot analysis.

**Western immunoblotting**

PMNLs (1 × 10^6 cells/mL, 0.3 ml) in HBSS/HEPES were incubated with or without 100 nM SkQ1 for 30 min at 37°C in 5% CO2 humidified atmosphere, then 1 µM A23187 for 10 min or 5 µM cytochalasin B (10 min) followed by 0.1 µM fMLP (10 min), or OZ (0.04 mg/ml, 10 min) were added. PMNLs were lysed in hot 2x Laemmli Sample Buffer. Equal amounts of protein (=20 µg total protein per lane), separated onto 12% SDS polyacrylamide gels and then transferred to PVDF membranes (Amersham, United States). Membranes were probed with antibodies against p-38, phospho-p38, ERK1/2, phospho-ERK1/2 (Cell Signaling, United States, ## 9212S, 9211S, 9102S, and 9101S, respectively). Membranes were treated with goat anti-rabbit HRP-conjugated secondary antibody (Sigma, United States) and developed with ECL extended duration substrate (ThermoFisher, United States) according to the manufacturer’s protocol. ChemiDoc System (Bio-Rad, United States) and appropriate software were used for visualizing and blot analysis.

**Statistical analysis**

To quantify leukotriene synthesis, two-way ANOVA followed by Tukey’s multiple comparisons test was performed, and graphs were plotted using GraphPad Prism version 9.2.0 software for Windows. Results are presented as mean ± SEM. Differences with p-value of <0.05 were considered statistically significant.

**Results**

**Mitochondria-targeted antioxidants inhibit the synthesis of leukotrienes in neutrophils**

As shown in Figures 1A–C, the mitochondria-targeted antioxidant SkQ1 dose-dependently inhibits the synthesis of...
LTB4, the omega-hydroxylation product of LTB4 (ω-LTB4) and total leukotrienes (ΣLTs). This effect of SkQ1 was observed upon activation of neutrophils by three different stimuli: the Ca²⁺ ionophore A23187, the chemotactic formyl-peptide fMLP in combination with cytochalasin B (CB_fMLP), and opsonized zymosan (OZ). In all three models, 100 nM SkQ1 almost completely inhibited leukotriene synthesis, while the SkQ1 analogue lacking the antioxidant quinone moiety (C12TPP) was ineffective. SkQ1 alone, without additional stimuli, did not induce 5-LOX product synthesis in neutrophils (data not shown). Trypan blue exclusion showed no decrease in viability of PMNL cells exposed to SkQ1 (45 min, 37°C) (n = 6).

To test the direct effect of SkQ1 on 5-LOX in a cell-free assay, we determined the effect of SkQ1 on 5-LOX product synthesis in cell homogenates (Supplementary Figure S2). 5-HPETE/5-HETE was the predominant product in the cell-free assay. It was shown that 100 and 200 nM SkQ1, which almost completely inhibited 5-LOX product synthesis in intact cells, had no significant effect on the activity of 5-LOX in the cell homogenate. We cannot rule out that SkQ1 at higher concentrations may directly inhibit 5-LOX, but this effect is unlikely to be responsible for the action of SkQ1 in intact cells. Moreover, as we have shown earlier using the fluorescent analog of SkQ1 (Vorobjeva et al., 2017), it is almost exclusively located in mitochondria of neutrophils, while 5-LOX is activated in the cytosol and at the nuclear membrane (Radmark et al., 2007).

The data on Figures 1A–C suggest that ROS produced in mitochondria (mtROS) are required for the synthesis of leukotrienes in neutrophils. In support of this possibility, a non-targeted antioxidant, a water-soluble analogue of vitamin E (Trolox), also inhibited the synthesis of leukotrienes, although at much higher concentration than SkQ1 (Figures 1D–F). Long-chain vitamin E analogs and metabolites have previously been reported to be effective inhibitors of 5-LOX (Neukirch et al., 2021). However, short-chain analogs like Trolox were ineffective, so direct inhibition of 5-LOX by Trolox can be ruled out.

To further elucidate the role of oxidative events in the regulation of leukotriene synthesis, we used diamide, an oxidizing agent that specifically converts glutathione to its disulfide (Kosower et al., 1969). In earlier studies, diamide has been shown to stimulate 5-LOX in arachidonic acid-activated neutrophils (Hatzelmann and Ullrich 1987). Diamide only slightly stimulated the synthesis of leukotrienes in neutrophils activated by A23187, but significantly weakened the inhibitory effect of 50 nM SkQ1 (Supplementary Figure S3). Higher doses of SkQ1 almost completely inhibited
leukotriene synthesis even in the presence of diamide. Higher concentrations of diamide also had an inhibitory effect in line with earlier findings (Hatzelmann and Ulrich 1987). These data are consistent with our assumption that SkQ1 inhibits leukotriene synthesis by suppressing the action of ROS.

It has been previously reported that SkQ1 stimulates the transcription factor NRF2 (nuclear factor erythroid-2-related factor 2), presumably through the activity of an electrophilic functional group in the quinone ring (Vnukov et al., 2017). NRF2 controls the expression of various antioxidant enzymes not associated with mitochondria, so it was necessary to analyze its possible role in inhibition of leukotriene synthesis by SkQ1. To do this, we applied the powerful NRF2 inducer sulforaphane (SFN) but found no effect on leukotriene synthesis (Figures 1D–F). To further explore the role of mtROS, we used one more mitochondria-targeted antioxidant MitoQ, which has less pronounced electrophilic functional groups for NRF2 activation. As shown in Figures 1D–F, this antioxidant effectively inhibits the synthesis of leukotrienes. Thus, the role of NRF2 in the effect of SkQ1 can be ruled out.

In our previous studies (Vorobjeva et al., 2017; Vorobjeva et al., 2020), we have shown that SkQ1 prevents NADPH oxidase (NOX2) activation in neutrophils activated by A23187 or fMLP. NOX2 is a powerful source of ROS in activated neutrophils; therefore, its role in the synthesis of leukotrienes was analyzed. We used an effective (albeit non-selective) NADPH oxidase inhibitor diphenyleneiodonium (DPI) and did not observe inhibition of LTB4 synthesis (Figures 1D–F). These data are consistent with findings that neutrophils from patients with chronic granulomatous disease (CGD) (i.e., those with genetic defects in NOX2) produce more LTB4 than normal neutrophils, and that LTB4 causes increased neutrophilic lung inflammation in CGD mice (Song et al., 2020). As shown in Figures 1D–F, DPI significantly increased LTB4 accumulation while suppressing ω-LTB4 production under all three stimuli, indicating the inhibition of LTB4 omega-hydroxylation. Consistent with this suggestion, DPI has previously been shown to inhibit two major components that catalyze omega-hydroxylation, flavin-containing cytochrome P450 reductase and cytochrome P450 itself (Szilagyi et al., 2016). 5-LOX catalyzes the first two steps in the biosynthesis of LTB4 and other leukotrienes from arachidonic acid (AA). Production of AA from phospholipids is catalyzed by phospholipase A2 (PLA2), and both enzymes can be inhibited by SkQ1. To analyze the possible role of PLA2 in the inhibition of leukotriene synthesis by SkQ1, we measured A23187-induced leukotriene synthesis in the presence of exogenous AA. As shown in Supplementary Figure S4, the addition of AA did not affect the inhibitory effect of SkQ1. These data do not allow a conclusion about possible effect of SkQ1 on PLA2, but clearly indicate that possible changes in PLA2 activity are not responsible for the effect of SkQ1 on leukotriene synthesis. We hypothesize that activation of 5-LOX is responsible for mtROS-dependent activation of leukotriene synthesis in neutrophils.

The effect of SkQ1 on the synthesis of leukotrienes is not mediated by changes in cytosolic Ca2+ concentration

Activation of leukotrienes synthesis depends on an increase in cytosolic Ca2+ concentration ([Ca2+]c) in stimulated neutrophils (Rouzer and Samuelsson 1987; Radmark et al., 2007). We analyzed the effect of SkQ1 and C12TPP on [Ca2+]c changes and found that both SkQ1 and C12TPP statistically significantly suppressed the [Ca2+]c increase induced by the combination of fMLP with CB, but not A23187 or zymosan (Figures 2A–G). It is important to note that the amplitude of increase in [Ca2+]c induced by fMLP was approx. 3 times higher than that of A23187 and zymosan (Figure 2G). At the same time, the increase in [Ca2+]c induced by A23187 lasted much longer, which probably explains the stronger stimulation of leukotriene synthesis compared to fMLP or zymosan (Figure 1). The difference between the effects of fMLP and A23187 likely reflects fMLP-induced opening of the store-operated Ca2+ channels (Itagaki et al., 2002; Tintinger and Anderson 2004), while A23187 additionally stimulates Ca2+ entry into the cytosol by increasing plasma membrane permeability (Mahomed and Anderson 2000). If so, then SkQ1 and C12TPP may act to deplete intracellular Ca2+ stores which prevents the store-operated channels from opening. In support of this, we have shown that SkQ1 and C12TPP by themselves cause a marked increase in [Ca2+]c (Figure 2H).

C12TPP inhibits the fMLP-induced [Ca2+]c increase to the same extent as SkQ1 but does not affect leukotriene synthesis. These data suggest that the effect of SkQ1 on fMLP-induced leukotriene synthesis is not entirely mediated by changes in [Ca2+]c. Any role of [Ca2+]c alterations in SkQ1-dependent inhibition of leukotriene synthesis induced by A23187 or OZ can be ruled out.

Activation of mitogen-activated protein kinases is upstream targets for SkQ1-dependent inhibition of leukotriene synthesis in neutrophils

To study the role of these kinases in the stimulation of leukotriene synthesis by the stimuli used above, we used the p38 inhibitor SB203580 and U0126, which inhibits the MAPK MEK kinase that activates ERK1/2. As shown in Figures 3A–C, SB203580 significantly inhibited leukotriene synthesis induced by fMLP in combination with CB but had no effect on synthesis induced by A23187 or zymosan. In contrast, U0126 almost completely suppressed leukotriene synthesis induced by any of the three stimuli.

Next, we analyzed whether p38 or ERK1/2 activation could be targets for modulation by SkQ1. SkQ1 was found to effectively prevent p38 and ERK1/2 phosphorylation (only phosphorylated
forms of these kinases are active) induced by A23187 and CB/fMLP, and OZ (Figures 3D–G). These data suggest that activation of both kinases can be an upstream target for mtROS upon activation of leukotriene synthesis.

Possible mechanisms of mtROS production responsible for synthesis of leukotrienes

The main sites for the production of ROS in mitochondria are complex I and complex III of the electron transport chain. In complex I, ROS can be formed either during the oxidation of NADH or during the energy-dependent reduction of NAD+ (reverse electron transfer, RET) (Vinogradov and Grivennikova 2016; Yin and O’Neill 2021). As shown in Figure 4, the complex I inhibitor piericidin only partially inhibits leukotriene synthesis induced by all tested stimuli. The effectiveness of piericidin (1 μM) as a respiration inhibitor was confirmed in experiments with highly respiring HeLa cells (data not shown). Thus, RET-dependent ROS production may be only partially responsible for the activation of leukotriene synthesis in neutrophils.

It can be assumed that the production of mtROS upon stimulation of neutrophils depends on the accumulation of Ca2+ in mitochondria which is driven by transmembrane electrical potential (ΔΨ) and mediated by the mitochondrial calcium uniporter (De Stefani et al., 2011). Multiple mechanisms of Ca2+-induced mtROS have not been fully elucidated (Adam-Vizi and Starkov 2010). We analyzed the effects of the uncoupler of oxidative phosphorylation carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) and

![FIGURE 2](https://example.com/figure2.png)

Effect of SkQ1, C12TTP and FCCP on cytosolic calcium levels in human neutrophils. PMNLs loaded with fura-2 dye (4 × 10^5 per sample) were pre-incubated for 30 min in HBSS/HEPES medium, treated with indicated doses of SkQ1, C12TTP or FCCP for 30 min and stimulated with 1 μM A23187, sequential addition of 5 μM cytochalasin B (10 min) and 0.1 μM fMLP or OZ (0.04 mg/ml). Fluorescence intensity at 510 nm of Ca2+-bound and Ca2+-free Fura-2 was measured every second for 120 s after the addition of stimuli (A–G) or immediately after the addition SkQ/C12TTP (h). Changes in [Ca2+]c, are presented as typical blank corrected curves of fura-2 fluorescence ratio 355/380 (A–C,H). Areas under curves within the measurement interval in arbitrary units (AUC, a.u.) are presented on (D–F) as means ± SEM (n = 4; *p < 0.05, **p < 0.01 compared to control values; by one-way ANOVA followed by Dunnett’s multiple comparisons test). Differences between the maximum and minimum values of F340/F380 (peak heights, a.u.) were assessed within the measurement interval and presented on (g) as means ± SEM (n = 4; *p < 0.05, ****p < 0.0001, compared to corresponding control values; ****p < 0.0001 for pairs of data indicated by brackets; by two-way ANOVA followed by Tukey’s multiple comparison test).
the inhibitor of respiration antimycin A, which dissipate ΔΨ, and observed strong inhibition of leukotriene synthesis induced by all tested stimuli (Figure 4). These data suggest that ΔΨ-dependent accumulation of Ca²⁺ in mitochondria is important for stimulation of leukotriene synthesis. 

FIGURE 3
Effect of p38 inhibitor SB203580 and ERK1/2 inhibitor U0126 on leukotriene synthesis in human neutrophils (A–C) and effect of SkQ1 on p38 and ERK1/2 phosphorylation (D–G). Before treatment, PMNLs (1–1.2) × 10⁷/ml at (A–C), 5 ml x 10⁷/0.5 ml at (D–G) were pre-incubated for 10 min at 37°C in CO₂ incubator. Then cells were treated 30 min with reagents indicated on X-axis (A–C) or with 100 nM SkQ1 (d,e,f,g, where indicated). After that, 1 µM A23187 (for 10 min) or, sequentially, 5 µM cytochalasin B (for 10 min) and 0.1 µM fMLP (for 10 min) or 0.04 mg/ml OZ (for 10 min), were added, as indicated. (A–C) The 5-LOX products were analyzed using HPLC, and data for LTB₄, ω-OH-LTB₄ and the sum of leukotrienes (ΣLTs = LTB₄ + trans-LTB₄ + ω-OH-LTB₄) are presented. Values present mean ± SEM of three independent experiments performed in duplicate. *p < 0.05; **p < 0.01; ****p < 0.0001 for pairs of data (marked column compared with corresponding control value) by two-way ANOVA followed by Tukey’s multiple comparison test. (D–G) PMNLs lysates were separated onto 12% SDS polyacrylamide gels, then blotted to PVDF membranes and probed with antibodies against p-p38, phospho-p38, ERK1/2, phospho-ERK1/2 as described in Methods. Representative Western biots are shown (D,E). The ratios of phospho-p38 to p38 and phospho-ERK1/2 to ERK1/2 (F,G) are plotted as means ± SEM of three independent experiments, **p < 0.01 for pairs of data indicated by brackets.

FIGURE 4
Effect of FCCP, Piericidin (Pieri) and Antimycin A (Antim) on leukotriene synthesis in human neutrophils. Before treatment, PMNLs (1–1.2) × 10⁷/6 ml were pre-incubated for 10 min at 37°C in CO₂ incubator. Then cells were treated 30 min with reagents indicated on X-axis. After that, A23187 (1 µM) (A) or cytochalasin B (5 µM) (B) or OZ (0.04 mg/ml) (C) were added for 10 min, then fMLP (0.1 µM) for 10 min (B), as indicated. Values present mean ± SEM of three or more independent experiments performed in duplicate. The 5-LOX products were analyzed using HPLC, and data for LTB₄, ω-OH-LTB₄ and the sum of leukotrienes (ΣLTs = LTB₄ + trans-LTB₄ + ω-OH-LTB₄) are presented. *p < 0.05, **p < 0.01, ****p < 0.0001 for pairs of data (marked column compared with corresponding control value) by two-way ANOVA followed by Tukey’s multiple comparison test.
In extreme cases, mitochondrial Ca\textsuperscript{2+} overload can open a large non-selective pore in the mitochondrial inner membrane (mitochondrial permeability transition pore, mPTP) and increase ROS production (Antonucci et al., 2021). Opening of the mPTP in neutrophils stimulated by fMLP or A23187 was demonstrated recently (Vorobjeva et al., 2020). As shown in Figures 1D–F, no effect of the mPTP inhibitor cyclosporine A was observed, indicating that the mPTP opening does not mediate mtROS production responsible for stimulation of leukotriene synthesis in neutrophils.

To further analyze the effect of FCCP, we measured the increase in cytoplasmic Ca\textsuperscript{2+} induced by various stimuli after pretreatment of neutrophils with FCCP. As shown in Figures 2A–G, FCCP slightly reduced the increase in cytoplasmic Ca\textsuperscript{2+} induced by A23187 and OZ, but strongly prevented the effect of CB_fMLP combination. Possible mechanisms for these effects of FCCP and their role in the inhibition of leukotriene synthesis need further study.

Discussion

Neutrophils are traditionally considered as cells with a few mitochondria, the energetics of which strongly depends on glycolysis (Curi et al., 2020). For long time it was generally accepted that mitochondria in neutrophils are involved only in apoptosis among cellular programs. The first indications of an important role of mtROS in neutrophils functions were presented by Daiber and coworkers (Kroller-Schon et al., 2014), who found that myxothiazol, the inhibitor of Complex III of respiratory chain stimulates NADPH oxidase in human neutrophils and this effect was blocked by mitochondria-targeted antioxidant MitoTEMPO. Later we have shown that activation of NADPH oxidase in neutrophils by fMLP (Vorobjeva et al., 2017) or by A23187 (Vorobjeva et al., 2020) are mediated by mtROS and blocked by mitochondria-targeted antioxidant SkQ1. The similar interplay between mtROS and NADPH oxidase was described also in endothelial cells stimulated with angiotensin II (Doughan et al., 2008), in smooth muscle cells subjected to hypoxia (Rathore et al., 2008), and in immortalized lymphoblast cell line activated with PMA (Dikalov et al., 2012). In our previous studies we demonstrated that mtROS are involved in degranulation of neutrophils (Vorobjeva et al., 2017) and in formation of neutrophil extracellular traps (NETs) (Vorobjeva et al., 2020) mostly due to activation of NADPH oxidase. Moreover, in neutrophils from the patients with chronic granulomatous disease (CGD) lacking active NADPH oxidase mtROS were found critical for A23187-dependent NETs formation demonstrating that some targets of mtROS aside NADPH oxidase are important for neutrophils functions.

In the present study we demonstrated that stimulation of leukotriene synthesis, which does not depend on activation of NADPH oxidase, is prevented by two mitochondria-targeted antioxidants (SkQ1 and MitoQ) and by the uncoupler of oxidative phosphorylation FCCP (Figure 1). The SkQ1 analogue lacking the antioxidant quinone moiety (C12TPP) was ineffective while non-targeted antioxidant Trolox inhibited the synthesis of leukotrienes at much higher concentrations than SkQ1. It was shown that SkQ1 at the concentrations that almost completely block leukotriene synthesis in intact neutrophils did not affect 5-LOX activity in cell homogenate (Supplementary Figure S2). These data suggest that ROS produced in mitochondria (mtROS) are required for the synthesis of leukotrienes in neutrophils. The effect of SkQ1 was mediated by inhibition of 5-LOX (catalyzing a rate-limiting reaction of LTB4 synthesis) rather than PLA2 (producing arachidonic acid for LTB4 synthesis) since application of exogenous arachidonic acid did not affect the inhibitory action of SkQ1 (Supplementary Figure S4).

An important mechanism of mtROS production in some cells, including macrophages, depends on reverse electron transfer (energy-dependent reduction of NAD+, RET) catalyzed by complex I of the electron transport chain (Vinogradov and Grivennikova 2016; Yin and O’Neill 2021). We have shown that the complex I inhibitor picrotien only partially inhibits leukotriene synthesis induced by all tested stimuli (Figure 4), indicating that RET may be only partially responsible for the activation of leukotriene synthesis in neutrophils.

Inhibition of leukotriene synthesis by SkQ1 was observed upon neutrophils activation with three different stimuli either mediated by the different receptors (fMLP and zymosan) or receptor independent (A23187). The common intermediate in signaling induced by these three stimuli is an increase in cytosolic Ca\textsuperscript{2+} concentration ([Ca\textsuperscript{2+}]c). We suggested that mtROS production was stimulated at high [Ca\textsuperscript{2+}]c, due to energy-dependent accumulation of Ca\textsuperscript{2+} in mitochondrial matrix. In agreement with this assumption dissipation of mitochondrial transmembrane potential with FCCP or antimycin A (an inhibitor of complex III of electron-transport chain) inhibited leukotriene synthesis (Figure 4).

An increase in [Ca\textsuperscript{2+}]c in the mitochondrial matrix can stimulate mtROS production through various mechanisms, including stimulation of NADH production by matrix dehydrogenases, stimulation of nitric oxide synthase, etc. (Adam-Vizi and Starkov 2010). The binding of Ca\textsuperscript{2+} to cardiolipin can strongly modulate the functions of the electron transport chain components and cause dissociation of cytochrome c from the membrane, slowing down the transfer of electrons from complex III to complex IV and, therefore, enhancing the formation of ROS (Brookes et al., 2004). Another mechanism for increased mtROS production depends on Ca\textsuperscript{2+}-dependent opening of the mitochondrial permeability......
transition pore (mPTP) (Antonacci et al., 2021). It has been suggested that the opening of mPTP mediates myxothiazol-dependent activation of NADPH oxidase in neutrophils (Kroller-Schon et al., 2014). We recently showed that mPTP-dependent mtROS production mediates the activation of NADPH oxidase by fMLP and A23187 as well as A23187-induced NETs formation (Vorobjeva et al., 2020). Here, we demonstrated that the mPTP inhibitor cyclosporine A did not affect leukotriene synthesis (Figure 1). Thus, the production of mtROS, which is responsible for the activation of leukotriene synthesis, does not depend on the opening of mPTP, in contrast to the stimulation of NADPH oxidase and the formation of NETs. Probably, this difference reflects the different sensitivity of the neutrophil responses to mtROS. In support of this assumption, leukotriene synthesis was completely inhibited at 100 nM SkQ1 (Figure 1), while complete inhibition of NADPH oxidase was reached only at 600 nM SkQ1, and NETs formation was not fully inhibited even at this concentration (Vorobjeva et al., 2020).

In search of downstream targets of mtROS involved in activation of leukotriene synthesis, we analyzed the role of MAP kinases Erk1/2 and p38. Using selective inhibitors, we demonstrated that ERK1/2 activity is critical for activation of leukotriene synthesis induced by any of the three stimuli, while activity of p38 is required only for activation with fMLP (Figure 3). SkQ1 prevents p38 and ERK1/2 activation induced by A23187, fMLP, or OZ (Figures 3D–G) suggesting that activation of both kinases is dependent on mtROS production. Activation of MAP kinases by upstream kinases depends on ATP and the effect of SkQ1 could be potentially mediated by ATP depletion. However, ATP supply in neutrophils fully depends on glycolysis (Curi et al., 2020), so the depletion of ATP by SkQ1 seems unlikely.

Both ERK1/2 and p38 are activated by upstream kinases at a conserved threonine-glutamate (or proline)-tyrosine motifs, and complete activation requires both Tyr and Thr phosphorylation (Payne et al., 1991; Zarubin and Han 2005). Phosphotyrosine levels are regulated by a large family of protein-tyrosine phosphatases (PTPs) that have a conserved cysteine residue, which is essential for catalysis and very susceptible to oxidation (Salmeen and Barford 2005). Inhibition of PTPs by ROS (especially hydrogen peroxide) is a key event in many signaling pathways initiated by growth factors (Lambeth 2004), angiotensin II (Tabet et al., 2008), hypoxia/reoxygenation (Sandin et al., 2011), etc. In neutrophils PTPs are specifically activated via inhibitory receptors which terminate their responses (Futosi et al., 2013). Receptor PTPs are inactivated by ROS, which are transiently and locally generated within cells by NADPH oxidases (Lambeth 2004), while the sources of ROS that inactivates non-receptor PTPs may be different. MtROS can inactivate PTPs either via activation of NADPH oxidases or directly. An example of direct inhibition of PTPs (in particular, PTP with dual-specificity DUSP6) by mtROS and subsequent ERK1/2 stimulation was presented in cervical carcinoma cells (Shagieva et al., 2017). Another PTP, that is, directly inhibited by mtROS is PTEN (phosphatase and tensin homolog deleted on chromosome 10) (Kim et al., 2018). Interestingly, PTEN is one of the main targets of ROS, during activation of inflammatory NF-κB signaling leading in particular to expression of cyclooxygenase and production of prostanooids (St-Germain et al., 2004). The above data indicate that mtROS directly inhibits PTPs that counteracts activation of ERK1/2 and p38, thereby causing activation of leukotriene synthesis in neutrophils.

Phosphorylation of 5-LOX by MAPKs together with Ca2+ stimulates translocation of the enzyme from the cytoplasm to the nuclear membrane, where it colocalizes with cPLA2 and 5-LOX-activating protein (FLAP) (Radmark et al., 2007). Translocation of 5-LOX to the nuclear membrane makes an important contribution to its activation so it may be one of the targets for SkQ1-dependent inhibition of leukotriene synthesis. Our data do not allow us to exclude other targets. For example, the production of arachidonic acid hydroperoxides, which are involved in the synthesis of leukotrienes, can be inhibited by SkQ1.

Dysregulation of leukotriene synthesis has long been associated with various pathologies associated with excessive inflammation, including asthma (Gelfand 2017), cardiovascular disease (Haugstrom 2018), ischemic and toxic acute kidney injury (Noiri et al., 2000; Deng et al., 2017), neurological (Saiwai et al., 2010), neurodegenerative (Giannopoulos et al., 2015), as well as ophthalmic diseases (Hirakata et al., 2020; Sanchez-Tabernero et al., 2021), including uveitis (Liao et al., 2006) and dry eye syndrome (Chistyakov et al., 2020). In recent years, many 5-LOX inhibitors have been considered, both synthesized and found in nature, but their clinical usefulness has not been tested. Zileuton (trade name Zylo) is the only active 5-LOX inhibitor marketed worldwide for the treatment of asthma. Mitochondria-targeted antioxidants have been proposed as a promising therapy for almost the same range of pathologies listed above (Zielonka et al., 2017; Zinovkin and Zamyatnin 2019). SkQ1 has been successfully used in preclinical studies for the treatment of cardiovascular and renal diseases (Bakeeva et al., 2008; Plotnikov et al., 2019), and also demonstrated anti-inflammatory activity in acute bacterial infection (Plotnikov et al., 2013) and in the systemic inflammatory response syndrome (SIRS) model (Zakharova et al., 2017). The high efficiency of eye drops containing SkQ1 has been demonstrated not only in various models of eye diseases in animals (Neroev et al., 2008; Zernii et al., 2017), but also in a clinical study of dry eye syndrome (Brzhesky et al., 2015). The coincidence of these two lists of pathologies suggests that inhibition of 5-LOX product synthesis by SkQ1 may contribute to the therapeutic efficacy of this compound. The use of mitochondria-targeted antioxidants may be an important
component in the treatment of pathologies associated with dysregulation of leukotriene synthesis.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving human participants were reviewed and approved by the Bioethics Committee of the Lomonosov Moscow State University, Application # 6-h, version 3, Bioethics Commission meeting # 131-d held on 31.05.2021. The patients/participants provided their written informed consent to participate in this study.

Author contributions

Conceptualization, BC and GS; methodology, EG, AP, TG, and GS; investigation, GS, EG, AP, and NK; writing—original draft preparation, GS and BC; writing—review and editing, BC, TG, and GS; funding acquisition GS. All authors contributed to the article and approved the submitted version.

References

Adam-Vini, V., and Starkov, A. A. (2010). Calcium and mitochondrial reactive oxygen species generation: how to read the facts. J. Alzheimers Dis. 20, 5415–5426. doi:10.3233/JAD-2010-100465

Alekseev, D. A., Zagradykaya, A. N., Pushkarova, M. A., Bachschmid, M., Peters-Golden, M., Wertz, O., et al. (2006). Cholesterol and its anionic derivatives inhibit 5-lipoxygenase activation in polymorphonuclear leukocytes and MonoMac6 cells. FEBS J. 273, 548–557. doi:10.1111/j.1742-4658.2005.00587.x

Antonenko, Y. N., Avestayn, A. V., Bakeeva, L. E., Chernyuk, B. V., Chertkov, V. A., Domriza, L. V., et al. (2008). Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives synthesis and in vitro studies. Biochemistry. 73, 1273–1287. doi:10.1134/S0006297908120018

Antonucci, S., Di Lisa, F., and Kaludercic, N. (2021). Mitochondrial reactive oxygen species in physiology and disease. Cell Calcium 94, 102344. doi:10.1016/j.celcalc.2020.102344

Bair, A. M., Turman, M. V., Vaine, C. A., Panettieri, R. A., Jr., and Soberman, R. J. (2012). The nuclear membrane leukotriene synthetic complex is a signal integrator and transducer. Mol. Biol. Cell 23, 4456–4464. doi:10.1091/mbc.E12-06-0489

Bakeeva, L. E., Barskov, I. V., Egorov, M. V., Isay, N. K., Kapelko, V. I., Kuzuchenko, A. V., et al. (2008). Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 2. Treatment of some ROS- and age-related diseases (heart arrhythmia, heart infarctions, kidney ischemia, and stroke). Biochemistry. 73, 1288–1299. doi:10.1134/S0006297908120024

Brookes, P. S., Yoon, Y., Robotham, J. L., Anders, M. W., and Sheu, S. S. (2004). Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Ann. J. Physiol. Cell Physiol. 287, C817–C833. doi:10.1152/ajpcell.00139.2004

Brzhesky, V. V., Efimova, E. L., Vorontsova, T. N., Alekseev, V. N., Gusarevich, O. G., Shaidurova, K. N., et al. (2015). Results of a multicenter, randomized, double-masked, placebo-controlled clinical study of the efficacy and safety of visomitin eye drops in patients with dry eye syndrome. Adv. Ther. 32, 1263–1279. doi:10.1007/s12323-015-0273-6

Burkert, E., Arnold, C., Hammarberg, T., Radmark, O., Steinshilber, D., and Wertz, O. (2003). The C2-like beta-barrel domain mediates the Ca2+-dependent resistance of 5-lipoxygenase activity against inhibition by glutathione peroxidase-1. J. Biol. Chem. 278, 42846–42853. doi:10.1074/jbc.M302471200

Chistyakov, D. V., Gancharova, O. S., Bakhreva, V. E., Tiulina, V. V., Goraiannov, S. V., Azbukina, N. V., et al. (2020). Inflammation in dry eye syndrome: Identification and targeting of oxylipin-mediated mechanisms. BioMedicines 8, E344. doi:10.3390/biomedicines08090344

Coffey, M., Peters-Golden, M., Fantone, J. C., and Sporn, P. H. (1992). Membrane association of active 5-lipoxygenase in resting cells. Evidence for novel regulation of the enzyme in the rat alveolar macrophage. J. Biol. Chem. 267, 570–576. doi:10.1016/S0021-9258(18)34853-2

Curi, R., Levada-Pires, A. C., Silva, E. B. D., Poma, S. O., Zambonatto, R. F., Domenech, P., et al. (2020). The critical role of cell metabolism for essential neutrophil functions. Cell. Physiol. Biochem. 54, 629–647. doi:10.1055/s-0039-1681004

De Stefani, D., Raffaello, A., Teardo, E., Szabo, I., and Rizzuto, R. (2011). A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 476, 336–340. doi:10.1038/nature10230

Deng, B., Lin, Y., Ma, S., Zheng, Y., Yang, X., Li, B., et al. (2017). The leukotriene B4-leukotriene B4 receptor axis promotes cisplatin-induced acute kidney injury by modulating neutrophil recruitment. Kidney Int. 92, 89–100. doi:10.1016/j.kint.2017.01.009

Dent, G., Rabe, K. F., and Magnussen, H. (1997). Augmentation of human neutrophil and alveolar macrophage LTB4 production by N-acetylcysteine: role of hydrogen peroxide. Br. J. Pharmacol. 122, 738–746. doi:10.1038/bj.180701428

Dikalov, S. I., Li, W., Doughtan, A. K., Blanco, R. R., and Zafari, A. M. (2012). Mitochondrial reactive oxygen species and calcium uptake regulate activation of phagocytic NADPH oxidase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R1134–R1142. doi:10.1152/ajpregu.00842.2010

Funding

This research was supported by the grant from the Russian Foundation for Basic Research (20–04–00816).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online: https://www.frontiersin.org/articles/10.3389/fphar.2022.1023517/full#supplementary-material
Doughan, A. K., Harrison, D. G., and Dikalov, S. I. (2008). Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ. Res. 102, 488–496. doi:10.1161/CIRCRESAHA.107.162800

Futasi, K., Fodor, S., and Mocsai, A. (2013). Neutrophil cell surface receptors and their intracellular signal transduction pathways. Int. Immunopharmacol. 17, 638–650. doi:10.1016/j.intimp.2013.06.034

Gefland, E. W. (2017). Importance of the leukotriene B4-BLT1 and LTB4-BLT2 pathways in asthma. Semin. Immunol. 33, 44–51. doi:10.1016/j.seminimunol.2017.08.005

Giannopoulos, P. F., Chu, J., Sprower, M., Li, J. G., Yu, W. H., Kirby, L. G., et al. (2015). Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy. Biol. Psychiatry 76, 693–701. doi:10.1016/j.biopsycho.2015.01.015

Golenkina, E. A., Galkina, S. I., Pletushkina, O., Chernyak, B., Gaponova, T. V., Romanova, V. M., et al. (2021). Gram-negative bacteria Salmonella typhimurium boost leukotriene synthesis induced by chemotactant FMLP to stimulate neutrophil swelling. Front. Pharmacol. 12, 84113. doi:10.3389/fphar.2021.121413

Grishina, Z. V., Pulkareva, M. A., Pletushkina, O. Y., Reiser, G., Peters-Golden, M., and Sud’ina, G. F. (2008). Sulfonates inhibit leukotriene synthesis in human polymorphonuclear granulocytes by a mechanism involving lipid rearrangement in intracellular membranes. Int. J. Biochem. Cell Biol. 40, 110–124. doi:10.1016/j.biocel.2007.07.001

Haeggstrom, J. Z. (2018). Leukotriene biosynthetic enzymes as therapeutic targets. J. Clin. Invest. 128, 2680–2690. doi:10.1172/JCI97945

Hammarberg, T., Provest, P., Persson, B., and Radmark, O. (2000). The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity. J. Biol. Chem. 275, 38787–38793. doi:10.1074/jbc.M001616200

Hammarberg, T., and Radmark, O. (1999). 5-lipoxygenase binds calcium. Biochemistry 38, 4441–4447. doi:10.1021/bi9824700

Hatzelmann, A., and Ullrich, V. (1987). Regulation of 5-lipoxygenase activity by the glutathione status in human polymorphonuclear leukocytes. Eur. J. Biochem. 169, 175–184. doi:10.1111/j.1432-1033.1987.tb13895.x

Hirakata, T., Matsuda, A., and Yokomizo, T. (2020). Leukotriene B4 receptors as targets. Int. Immunopharmacol. 83, 175–179. doi:10.1016/j.intimp.2020.01.009

Hirose, K., Yonemoto, T., Nakao, A., Izumi, T., Fujita, T., Kimura, S., et al. (2000). An in vivo approach showing the chemotactic activity of leukotriene B4(4) in acute renal ischemic-reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 97, 823–828. doi:10.1073/pnas.97.3.823

Hiroshini, K., and Peters-Golden, M. (2011). Leukotrienes and airway inflammation. Biochim. Biophys. Acta 1810, 1096–1102. doi:10.1016/j.bbadgen.2011.02.005

Payne, D. M., Rossomando, A. J., Martino, P., Erickson, A. K., Her, J. H., Shabanowitz, J., et al. (1991). Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J. 10, 885–892. doi:10.1002/j.1460-2075.1991.tb00821.x

Peters-Golden, M., and Henderson, W. R., Jr. (2007). Leukotrienes. N. Engl. J. Med. 357, 1841–1854. doi:10.1056/NEJMra071371

Plotnikov, E. Y., Morosanova, M. A., Pezvez, I. B., Zorova, L. D., Manskikh, V. N., Pulkova, N. V., et al. (2013). Protective effect of mitochondria-targeted antioxidants in an acute bacterial infection. Proc. Natl. Acad. Sci. U. S. A. 110, E3100–E3108. doi:10.1073/pnas.1307096110

Plotnikov, E. Y., Pezvez, I. B., Zorova, L. D., Chernyk, V. P., Prusov, A. N., Kireev, I. I. et al. (2019). Mitochondrial damage and mitochondria-targeted antioxidant protection in LPS-induced acute kidney injury. Antioxidants (Basel) 8, 176. doi:10.3390/antiox8060176

Rådmark, O. (2002). Arachidonate 5-lipoxygenase. Prostagl. Other Lipid Mediat. 68–69, 211–234. doi:10.1016/S0934-4824(01)00083-4

Radmark, O., Werz, O., Steinhilber, D., and Samuelsson, B. (2007). 5-Lipoxigenase: regulation of expression and enzyme activity. Trends Biochem. Sci. 32, 332–341. doi:10.1016/j.tibs.2007.06.002

Rathore, R., Zheng, Y. M., Niu, C. F., Liu, Q. H., Korde, A., Ho, Y. S., et al. (2008). Hypoxia activates NADPH oxide to increase [ROS] and [Ca2+] in the mitochondrial ROS-PCKeion signaling axis in pulmonary artery smooth muscle cells. Free Radic. Biol. Med. 45, 1223–1231. doi:10.1016/j.freeradbiomed.2008.06.012

Rothman, C. B., and Samuelsson, B. (1987). Reversible, calcium-dependent membrane association of human leukocyte 5-lipoxygenase. Proc. Natl. Acad. Sci. U. S. A. 84, 7393–7397. doi:10.1073/pnas.84.21.7393

Saiwai, H., Okawa, Y., Yamada, H., Kumamaru, H., Harada, A., Okano, H., et al. (2010). The LTB4-BLT1 axis mediates neutrophil infiltration and secondary injury in experimental spinal cord injury. Am. J. Pathol. 176, 2352–2366. doi:10.1016/j.ajpath.2010.09.0839

Salmeen, A., and Barford, D. (2005). Functions and mechanisms of redox regulation of cysteine-based phosphatases. Antioxid. Redox Signal. 7, 560–577. doi:10.1089/ars.2005.7.560

Sanchez-Tabernero, S., Fajardo-Sanchez, J., Weston-Davies, W., Parekh, M., Kriman, J., Kaye, S., et al. (2021). Dual inhibition of complement component 5 and leukotriene B4 by topical RVAS76 in atopic keratoconjunctivitis. TRACERphase 1 clinical trial results. Orphanet J. Rare Dis. 16, 270. doi:10.1186/s13023-021-01890-6

Sud’ina et al. 10.3389/fphar.2021.10235517

Frontiers in Pharmacology

11

frontiersin.org
Sandin, A., Dagnell, M., Gonon, A., Pernow, J., Stangl, V., Aspenstrom, P., et al. (2011). Hypoxia followed by re-oxygenation induces oxidation of tyrosine phosphatases. FEBS Letters 585, 1878–1882. doi:10.1016/j.febslet.2011.07.004

Shagieva, G., Domnina, L., Makarevich, O., Chernyak, B., Skulachev, V., and Dugina, V. (2017). Depletion of mitochondrial reactive oxygen species downregulates epithelial-to-mesenchymal transition in cervical cancer cells. Oncotarget 8, 4901–4913. doi:10.18632/oncotarget.13612

Song, Z., Huang, G., Chiap pesticides.

Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., et al. (2017). Low concentration of uncouplers of oxidative phosphorylation decreases the TNF-induced endothelial permeability and lethality in mice. Biochim. Biophys. Acta. Mol. Basis Dis. 1863, 968–977. doi:10.1016/j.bbadis.2017.01.024

Zubrin, T., and Han, J. (2005). Activation and signaling of the p38 MAP kinase pathway. Cell Res. 15, 11–18. doi:10.1038/sj.cr.7290257

Zernyi, E. Y., Gancharova, O. S., Bakheeva, V. E., Golovastova, M. O., Kabanova, E. I., Savchenko, M. S., et al. (2017). Mitochondria-targeted antioxidant SkQ1 prevents anesthesia-induced dry eye syndrome. Oxid. Med. Cell. Longev. 2017, 9281519. doi:10.1155/2017/9281519

Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., et al. (2017). Mitochondria-targeted triphenylphosphonium-based compounds: Syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem. Rev. 117, 10043–10120. doi:10.1021/acs.chemrev.7b00042

Zinovkin, R. A., and Zamyatnin, A. A. (2019). Mitochondria-targeted drugs. Curr. Mol. Pharmacol. 12, 202–214. doi:10.2174/1874467212666181127151059